Protection against any potential coronavirus vaccine may be short-lived and may require reinforcement to extend protection, said White House Health Advisor Dr. Anthony Fauci on Monday.
As several companies get closer to the finish line of a potential vaccine against the virus, the role of antibodies becomes even more important because it can determine how well any vaccine works and how often someone might need to get one or an accelerator to extend protection.
When asked how long antibodies can provide some protection against infection, Fosi said on Monday that “we don’t know.”
“Using this spiky protein, which is presented as we do it with prime numbers and in some cases increases, we will assume that there is a degree of protection, but we must assume that it will be finite,” he said. added during a Q & A discussion with Dr. Francis Collins, director of the National Institutes of Health. “It won’t be like a measles vaccine.”
The measles, mumps and rubella vaccine usually provides lifelong immunity. according to the Centers for Disease Control and Prevention“Any potential coronavirus vaccine is unlikely to do the same,” said Fauchi.
“So in these cases, surveillance will continue to find out if we need a raise,” he said. “We may need support to continue the defense. But now we don’t know how long it will last. ”
Fauci, director of the National Institute of Allergy and Infectious Diseases, added that reports of recovered patients with Covid-19 virus-reinfected viruses are probably inaccurate. He said it was more likely that the test used to detect Covid-19 probably detected fragments of the virus still in the body of the recovered patient, but they probably were not re-infected.
“There are no documented cases where people got better and got sick again in the sense of virus propagation,” he said. “I won’t be surprised if there is a rare case when a person fell into remission and fell into a relapse … But Francis, I can say with confidence that this is very unlikely if this is a common occurrence.”
He added that several other viruses, including Ebola, have demonstrated the ability to reinfect infected patients.
Fauci said earlier that there is a chance that the coronavirus vaccine will not be able to provide long-term immunity.
“When you look at the history of coronaviruses – common coronaviruses that cause colds – there are reports in the literature that the resistance of protective immunity ranges from three to six months and is almost always less than a year,” he said for the last time. month. “It’s not a lot of durability and protection.”
But any protection will be welcome, especially among vulnerable communities, such as health workers and older people, who are likely to be given priority in the form of emergency authorization when the vaccine is safe and effective for people, as senior US health officials said earlier. .
Officials are likely to know whether the candidate for the vaccine currently under development is safe and effective by early 2021, Fosi said on Monday, following a schedule that officials have been touting since March. AstraZeneca, a British pharmaceutical company, and Moderna, an American biotechnology firm, are the two most advanced companies in developing their vaccine candidates.
National Institutes of Health is collaborating with Moderna to accelerate the development of their potential vaccine as part of Operation Warp Speed, a federal effort to accelerate the development of coronavirus vaccines.
Modern is expected to move its candidate in three phases by the end of the month, although the company’s shares fell last week, when STAT News reported the company put off the date the test began. The third stage test is the most comprehensive test that a candidate will face, involving around 30,000 test participants. If all goes well and the candidate is safe and effective for people, the vaccine can be distributed before the end of the year.
The World Health Organization said last week that around the world, 16 companies with vaccine candidates are being tested in humans. More than 10 companies in the United States are already undergoing human trials or are preparing to start them soon.
“We hope that by the end of this year or the beginning of 2021, we will at least have an answer whether the vaccine or vaccines in the plural are safe and effective,” said Fauchi.